BIG Breast International Group
We will find a cure for breast cancer through global research and collaboration.

BIG 1-04 AZURE

The BIG 1-04 AZURE trial explores whether adjuvant zoledronic acid does reduce recurrence in patients with high-risk, localised breast cancer.

Coordinating groups: NCRI-BCSG, University of Sheffield (sponsor), CTRU (University of Leeds trials unit)

Patients accrual
Start date: September 2003
Closure date: January 2006
Target nr. of patients: 3300
Final accrual: 3360

Reason for closure: reached target accrual
ClinicalTrials.gov Identifier: NCT00072020

Publications

  • Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ, Ritchie D, Pugh J, Gaunt C, Rea U, Peterson J, Davies C, Hiley V, Gregory W, Bell R; AZURE Investigators. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med. 2011 Oct 13;365(15):1396-405. Epub 2011 Sep 25
  • Coleman R, Woodward E, Brown J, Cameron D, Bell R, Dodwell D, Keane M, Gil M, Davies C, Burkinshaw R, Houston SJ, Grieve RJ, Barrett-Lee PJ, Thorpe H. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer. Breast Cancer Res Treat. 2011 Jun;127(2):429-38. Epub 2011 Mar 11
  • Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, Keane MM, Gil M, Ritchie D, Passos-Coelho JL, Wheatley D, Burkinshaw R, Marshall SJ, Thorpe H; AZURE (BIG01/04) Investigators. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer. 2010 Mar 30;102(7):1099-105. Epub 2010 Mar 16
Scroll to top

Contact us

Breast International Group (BIG)-aisbl Blvd de Waterloo 121 B-1000 Brussels | Belgium VAT BE 0468 176 240